2 years) compared to alendronate (mean: 1
S
7 out of 10 from a total of 362 ratings on
Fosamax is also used to treat Paget's disease
Prolia contains the active drug denosumab, while Fosamax contains the active drug alendronate
Prolia® (denosumab) vs alendronate Study Design | Prolia® For the treatment of postmenopausal women with osteoporosis at high risk for fracture Head-to-head BMD
Prolia ® demonstrated noninferiority and superiority (vs alendronate) in total hip BMD 1,* increase in BMD vs alendronate The lower limit of the confidence interval excluded the
It affects more than 40 million Americans and results in more than 2 million fractures annually among Medicare
They identified 10 studies that compared denosumab with one of four bisphosphonates, most often alendronate (Fosamax) (n = 6)
2 percent and, after eight years, by 18
2 Based on data from the National Health and Nutrition Survey III (NHANES III), the National Osteoporosis Foundation in 2014 estimated that more than 9
Uses Prolia is used to treat bone loss and certain types of osteoporosis (a condition that causes Alendronate is a common drug for osteoporosis, but it may cause osteonecrosis of the jaws, especially after tooth extraction
read more
Int J Clin Pract
US Department of Health and Human Services
In women with postmenopausal osteoporosis, the overall incidence of new malignancies was 4
In addition, the risk of fractures is reduced by approximately 20%–50% by alendronate and 20%–70% by denosumab; alendronate with the highest protective effect on hip fractures and denosumab on vertebral fractures (17, 18)
Other alendronate side effects can be more serious, including esophageal ulcers and osteonecrosis of the jaw
But they each work differently because Prolia is a monoclonal antibody (it may also be called a miscellaneous bone resorption agent) and Reclast is a bisphosphonate which means they have different side effects, other uses Abstract
3 For the meta-analysis of denosumab versus bisphosphonates on risk of fracture, Lin et al
[1] Bisphosphonates are highly efficient antiresorptive drugs used to treat diseases with increased osteoclast activity such as cancer-related conditions, osteoporosis
Although there is no direct evidence of benefit in patients with one or more of these factors or in patients with very low bone mineral density or a